Market revenue in 2023 | USD 175.2 million |
Market revenue in 2030 | USD 265.5 million |
Growth rate | 6.1% (CAGR from 2023 to 2030) |
Largest segment | Outpatient facilities |
Fastest growing segment | Home Care |
Historical data | 2018 - 2022 |
Base year | 2023 |
Forecast period | 2024 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | Hospitals, Outpatient Facilities, Home Care, Research & Manufacturing |
Key market players worldwide | Abbott Laboratories, Thermo Fisher Scientific Inc, Roche Holding AG ADR, Qiagen NV, Siemens Healthineers AG ADR, Becton Dickinson & Co, Illumina Inc, Epigenomics AG, Koninklijke Philips NV, FUJIFILM Holdings Corp |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to liver cancer diagnostics market will help companies and investors design strategic landscapes.
Outpatient facilities was the largest segment with a revenue share of 61.99% in 2023. Horizon Databook has segmented the Brazil liver cancer diagnostics market based on hospitals, outpatient facilities, home care, research & manufacturing covering the revenue growth of each sub-segment from 2018 to 2030.
Brazil is anticipated to become the most lucrative market for liver cancer diagnostic products in Latin America. This can be attributed to high incidence and mortality rate due to liver cancer and government initiatives to increase early diagnosis and treatment of liver cancer in the country. According to the data published by GLOBOCAN, in 2018, liver cancer was the seventh most common cause of death among all cancers in Brazil.
In 2018, around 12,463 news cases of liver cancer were reported in Brazil, which lead to around 11,797 deaths. Also, chronic (long-term) hepatitis B virus (HBV) or hepatitis C virus (HCV) infection is found to be the most common cause of liver cancer in Brazil. According to an article published by NCBI in August 2017, prevalence of HBV was very high in South Brazilian regions (17.2 cases per 100,000 inhabitants).
Such, high prevalence of HBV and HCV in Brazilian regions may increase the risk of liver cancer, thus, driving demand for liver cancer diagnostic solutions in the country. However, limited availability of liver cancer imaging equipment in Brazilian public hospitals is expected to be a major factor hampering the market growth.
Horizon Databook provides a detailed overview of country-level data and insights on the Brazil liver cancer diagnostics market , including forecasts for subscribers. This country databook contains high-level insights into Brazil liver cancer diagnostics market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account